Transient Ischemic Attack Market SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2024 - 2031)
Transient Ischemic Attack Market is segemented By Drug Type (Anti-platelet Agents, Anticoagulants, Statins, Others), By Treatment Approach (Pharmacological Treatment, Surgical Intervention, Lifestyle Modification), By Route of Administration (Oral, Intravenous, Subcutaneous), By Geography (North America, Latin America, Asia Pacific, Europe, Middle East, and Africa). The report offers the value (in USD billion) for the above-mentioned segments.
Transient Ischemic Attack Market Size
Market Size in USD
CAGR6.2%
| Study Period | 2024 - 2031 |
| Base Year of Estimation | 2023 |
| CAGR | 6.2% |
| Market Concentration | High |
| Major Players | AstraZeneca, Bristol-Myers Squibb, Janssen LP, Boryung Pharmaceutical Co. Ltd, Orion Pharma |
please let us know !
Transient Ischemic Attack Market Analysis
The Global Transient Ischemic Attack Market is estimated to be valued at USD 1.34 Bn in 2024 and is expected to reach USD 2.03 Bn by 2031, growing at a compound annual growth rate (CAGR) of 6.2% from 2024 to 2031. The growing geriatric population is one of the key factors driving the market growth, as the risk of TIA increases with age. With an increasing elderly demographic, the market is expected to witness significant demand over the forecast period.
The market is witnessing increasing adoption of novel products for treatment and diagnosis of TIAs. Leading pharmaceutical companies are investing heavily in development of new drug formulations such as antiplatelets and anticoagulants to minimize neurological deficits post TIA. Furthermore, technological advancements in imaging such as CT angiography and MRI have improved diagnosis and management of TIAs. This is expected to support the market growth during the forecast period.